Clinical utility of alk fusion detection by liquid biopsy

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced the publication of a paper in the journal lung cancer, titled "clinical utility of next-generation sequencing-based ctdna testing for common and novel alk fusions". the study, jointly published by resolution bioscience (now a part of agilent) and memorial sloan kettering cancer center (msk), describes the use of plasma ctdna ngs to detect novel anaplastic lymphoma kinase (alk) fusions, and to serially moni
A Ratings Summary
A Quant Ranking